This site is intended for healthcare professionals

Phase IIIb ATLAS-2M study of Cabenuva + Edurant shows continued efficacy to week 96 in HIV.- ViiV Healthcare

Read time: 1 mins
Last updated:28th Jun 2021
Published:7th Mar 2021
Condition: HIV/AIDS
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest